NCT00420082View on ClinicalTrials.gov

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

December 31, 2006

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Bilastine

Encapsulated Bilastine 20 mg tablets Q.D.

DRUG

Fexofenadine

Encapsulated Fexofenadine 120 mg tablets Q.D.

DRUG

Cetirizine

Encapsulated Cetirizine 10 mg tablets Q.D.

DRUG

Placebo

Encapsulated Placebo tablets Q.D.

Trial Locations (1)

A-1150

Allergy Center Vienna West, Vienna

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
lead

Faes Farma, S.A.

INDUSTRY

NCT00420082 - A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber | Biotech Hunter | Biotech Hunter